Monoclonal antibody (mAb) therapies have shown some use in patients with mild to moderate COVID-19, but have limited efficacy in preventing complications or death in patients with severe COVID-19. Reporting in Nature, Ravetch, Bournazos and colleagues now demonstrate that optimizing mAbs for the engagement of activating Fcγ receptors (FcγRs) significantly improves their ability to confer full protection in SARS-CoV-2 challenge models. Moreover, these mAbs are also highly potent at reducing mortality post-infection in animal models of severe COVID-19. These findings illustrate the importance of FcγR-mediated pathways in antibody-mediated antiviral immunity and have important implications for the development of more effective mAb therapeutics.
References
Original article
Yamin, R. et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature https://doi.org/10.1038/s41586-021-04017-w (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Flemming, A. Fc-optimized monoclonal antibodies show superior efficacy. Nat Rev Immunol 21, 693 (2021). https://doi.org/10.1038/s41577-021-00636-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-021-00636-6